North Carolina is currently home to 2618 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
HEAL-IST IDE Trial
NCT05280093
Recruiting
Inappropriate Sinus Tachycardia (IST) is a prevalent and debilitating condition in otherwise healthy younger patients, resulting in significant loss of quality of life, lacking effective treatment options or systematic clinical evidence to support a therapy. The primary objective of this clinical trial is to evaluate the safety and effectiveness of a hybrid sinus node sparing ablation procedure for the treatment of symptomatic drug refractory or drug intolerant IST.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/13/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Inappropriate Sinus Tachycardia
Register for Updates
MRI in High-Grade Glioma Patients Undergoing Chemoradiation
NCT05212272
Recruiting
The purpose of this research study is to see if investigators can predict how brain functioning changes after radiation treatment based on PET scans and blood tests. Most participants experience at least mild decreases in their memory or attention after radiation therapy. Investigators hope that PET scans, lumbar puncture, and blood tests might help investigators predict who might have larger changes in their brain function after radiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: High Grade Glioma
Register for Updates
Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab
NCT05204290
Recruiting
The purpose of this research study is to find out what effects (good and bad) Pembrolizumab and radiosurgery have on participants with high-grade epidural disease of the spine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Epidural Spinal Tumors, Cancer
Register for Updates
An Evaluation of Insomnia Treatment to Reduce Cardiovascular Risk in Patients With Posttraumatic Stress Disorder
NCT04498754
Recruiting
Posttraumatic stress disorder (PTSD) is a chronic, debilitating psychiatric disorder that is associated with an increased risk of death due to cardiovascular disease (CVD). Most individuals with PTSD also have Insomnia Disorder. Sleep quality is also associated with risk factors for CVD. The objective of this study is to examine how insomnia contributes to CVD risk among people with PTSD. The investigators will also examine whether this risk can be decreased with treatment for Insomnia Disorder.
Gender:
ALL
Ages:
Between 40 years and 59 years
Trial Updated:
01/13/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Insomnia, Posttraumatic Stress Disorder, Cardiovascular Risk Factor
Register for Updates
Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients
NCT04217551
Recruiting
A multicenter, randomized, adaptive allocation clinical trial to determine if increasing durations of induced hypothermia are associated with an increasing rate of good neurological outcomes and to identify the optimal duration of induced hypothermia for neuroprotection in comatose survivors of cardiac arrest.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Cardiac Arrest, Out-Of-Hospital, Hypothermia, Induced, Hypoxia-Ischemia, Brain
Register for Updates
NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy
NCT03589339
Recruiting
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: University of North Carolina, School of Medicine, Chapel Hill, North Carolina
Conditions: Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastasis From Malignant Melanoma of Skin (Disorder), Metastasis From Malignant Tumor of Bladder (Disorder), Metastasis From Malignant Tumor of Liver, Metastatic Renal Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC
Register for Updates
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
NCT05868629
Recruiting
This study is a phase IV, pragmatic single-arm prospective, open label study in pediatric (6 years or older) and adult study participants with rare BRAF V600E mutation-positive unresectable or metastatic solid tumors for whom a decision has already been made to be treated with dabrafenib and trametinib, irrespective of the trial participation.
Gender:
ALL
Ages:
Between 6 years and 100 years
Trial Updated:
01/12/2025
Locations: Duke Clinical Research Institute, Durham, North Carolina
Conditions: Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
Register for Updates
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
NCT05484622
Recruiting
Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive isocitrate dehydrogenase-1 (IDH-1) mutant Glioma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2025
Locations: Duke University (Site: 840110), Durham, North Carolina
Conditions: Astrocytoma, Oligodendroglioma
Register for Updates
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
NCT06081894
Recruiting
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/11/2025
Locations: Sanger Heart & Vascular Institute - HCM Clinic, Charlotte, North Carolina
Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Register for Updates
Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset
NCT05685745
Recruiting
The goal of the Tiny Baby Collaborative Multicenter Inventory of Neonatal-Perinatal Interventions (MINI) minimum dataset is to serve as a registry detailing the outcomes and practices for all deliveries and infants admitted to intensive care at 22-23 weeks' gestation at participating hospitals.
Gender:
ALL
Ages:
Between 0 years and 1 year
Trial Updated:
01/10/2025
Locations: Duke University, Durham, North Carolina
Conditions: Infant, Extremely Premature, Obstetric Labor, Premature, Premature Birth, Intensive Care, Neonatal, Intensive Care Units, Neonatal
Register for Updates
Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)
NCT05579327
Recruiting
This is a double-blind, randomized phase 3 multicenter placebo-controlled study in at least 16 evaluable male participants diagnosed with MCT8 deficiency. Male participants, from 4 years of age (at randomization) and having demonstrated stable maintenance treatment with tiratricol, will be randomized to receive placebo or tiratricol for 30 days or until reaching rescue criterion (serum total triiodothyronine \[T3\] \> upper limit of normal \[ULN\] of the participant's normal range, for a sample... Read More
Gender:
MALE
Ages:
4 years and above
Trial Updated:
01/10/2025
Locations: Rare Disease Research, LLC, Hillsborough, North Carolina
Conditions: Monocarboxylate Transporter 8 Deficiency, Allan-Herndon-Dudley Syndrome
Register for Updates
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
NCT06179069
Recruiting
An Open-label, Multicenter Study of ZL-1310 as a Single Agent and In Combination with Atezolizumab to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Zai Lab Site 2018, Durham, North Carolina
Conditions: SCLC
Register for Updates